World Orphan Drug Congress EU 2020

Featured Presentations

Use of Novel AI/ML Tools to Support Patient Identification; Perspectives From the Syneos Health Rare Disease Consortium

Monday, November 2nd | 10 – 13:00 CET

Co-hosted by:

• Ray Huml, Vice President, Medical & Scientific Strategy, Rare Diseases Consortium

Making a Successful Transition from Orphan Drug Designation to Orphan Drug Exclusivity

Tuesday, November 3rd | 11:30 CET

Presented by:

• Zohra Lomri, Senior Director, Regulatory Consulting

Accelerating Rare Disease Drug Development in the COVID-19 Era and beyond.

Tuesday, November 3rd | 15:45 CET

Presented by:

• Zizi Imatorbhebhe , MS MBA Vice President, Global Clinical Drug Development, Rare Diseases
• Cinzia Dorigo, PharmD Vice President, Global Clinical Drug Development, Rare Diseases

New Models to Run Natural History Studies & Registries: Perspectives From Patients, Industry, CROs & Regulators on Sustainable RWE

Tuesday, November 3rd | 17:45 CET

Presented by:

• Javier Jimenez, Executive Vice President, RWE & Late Phase
• Ray Huml, Vice President, Medical & Scientific Strategy & Head, Rare Disease Consortium

An Integrated Development Plan in Rare & Orphan Medicinal Products (OMPs): Significantly Accelerating Time-to-Approval and Strengthening Asset Value for All Key Industry Stakeholders

Thursday, November 5th | 9:40 CET

Presented by:

• Maryna Kolochavina, PharmD, PMP, Executive Director, Syneos One